该站点未添加描述description...

该站点未添加描述description...

试压泵,电动试压泵,气动试压泵,手动试压泵,试压泵厂家,高压试压泵,大流量试压泵,试压泵压力曲线记录仪,试压泵控制系统,微机高压测试系统,井口试压系统等,电话:18980419018

奥卓新材是专业从事高性能减振降噪材料研发,生产及销售的科技企业,被评为国家高新技术企业,瞪羚企业,专精特新企业.公司研发制造的减振隔音垫产品应用于轨道交通,工业装备,建筑工程,宁静住宅领域.

一个专注于技术分享的博客平台,提供大家以共同学习,乐于分享,拥抱开源的价值观进行学习交流

HearTi的自用导航。

多映光电深圳有限公司致力于led灯带,LED侧光源大功率模组,LED注塑模组,LED贴片模组,LED广告灯箱模组光源,5050LED模组,LED3528模组研发生产,免费为广告标识公司提供LED照明解决方案

正信信用创新研发多项信用评价标准，形成了具有自主知识产权的信用评价标准、技术和评价模型。通过信用报告、信用评价、信用认证、信用培训、商账管理、信用管理等多样化信用产品与服务，满足国内各领域的信用服务需求。

掌易有声，是掌易灵动旗下的有声内容制作平台，支持内容创作，配音，话本标注，真人有声小说制作，TTS有声小说制作，有声内容承制，内容分销

该站点未添加描述description...

WestVacBiopharmaisfoundedbyAcademicianWeiYuquanfromWestChinaHospitalofSichuanUniversity,togetherwith10scientistsfromStateKeyLaboratoryofBiotherapy(SKLB).ItsheadquarterislocatedintheInternationalBio-Town,Chengdu.TheCEOofWestVacBiopharmaisProf.WeiYuquan,whoistheAcademicianofChineseAcademyofSciencesaswellastheDirectorofStateKeyLaboratoryofBiotherapy.WestVaciscommittedtoexploringthelatestbiotherapytechnologiesformajordiseases,includinginfectiousdiseases,malignanttumors,cardiovasculardiseases,andsoon.IthasattachedgreatimportanceintheResearchandDevelopment(R&D)ofCOVID-19vaccineespeciallyandbuildingaCOVID-19vaccineproductionplatform.StateKeyLaboratoryofBiotherapy(SKLB)wasestablishedbytheMinistryofSciencesandTechnologyofChinain2005andbecameoneoftheNationalR&DPlatformsforNovelDrugsfoundedbytheMinistriesofSciencesandTechnologyaswellasthatofHealthofChinain2008.ItisalsosupportedbyNationalCollaborativeInnovationProgramandhasbecometheNationalCollaborativeInnovationCenterforBiotherapysince2013.WestChinaHospitalofSichuanUniversity，foundedin1892,istheNationalCenterforDiagnosisandTreatmentofSevereandCriticalDiseasesinWesternChina.Itisalsotheworld’slargestcomprehensivehospitalcomplexlocatedinonecampusarea.RelyingonthemedicalresourcesofStateKeyLaboratoryofBiotherapyandWestChinaMedicalCenter,WestVachasadoptedrecombinantproteinmethodologytodeveloptheCOVID-19vaccine.Becauseofthesafetyoftheproteinvaccine,itisalsotheonlyCOVID-19vaccineapprovedfortheuseinchildrenover3yearsoldinChina.ThevaccinewasapprovedbytheNationalMedicalProductsAdministrationforclinicaltrialsonAugust21,2020.PhaseI/IIclinicaltrialshavebeencompleted,andphaseIIIclinicaltrialsarebeingcarriedoutinNepal,Kenya,Japanandothercountries.Thevaccinetargetsthespikeproteinbindingdomain(S-RBD)ofSARS-CoV-2,producingneutralizingantibodiestoblockCOVID-19infectionofhumancells.TheresultwaspublishedonNature,theworld’sfamousscientificjournalonJuly29th,2020.IthasalsobeenthefirstpaperofCOVIDvaccinepublishedbyNaturesincethepandemicoutbreak.TheS-RBDgeneoftheCOVID-19virusisintroducedintotheinsectcells,whichwereusedasafactorytoproducehigh-qualityrecombinantvaccineproteinandthendoesrefinedpurification.Suchtechnologyiseasytobemass-producedandbroughttothemarket.WestVacBiopharmaiscommittedtobecomingtheworld`sleadingvaccineandimmunotherapyplatform.

该站点未添加描述description...